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                                              ABSTRACT  
Alamri, Badrieah. M.S. Microbiology and Immunology Graduate 
Program, Wright State University, 2017. Effects of Myrrh on HSV Type 
1 Using Plaque Assay.  
 
Herpes simplex virus type 1 (HSV-1) is a highly infective human pathogen which infects 
a wide range of population in North America and worldwide. HSV-1 infection has two phases, 
lytic and latent. Recurrence of HSV-1 is a major challenge to clinicians to control the infection 
especially in immune depleted individuals. Acyclovir (ACV) is an antiviral drug used to treat 
HSV-1 infection. Low solubility of ACV in water, mutation of viral thymidine kinase, and 
mutation of viral DNA polymerase are major problems that cause usage limitations of ACV. 
Myrrh has been used as an analgesic and anti-inflammatory natural product in middle eastern 
countries for centuries. Recently Myrrh has shown a promising therapeutic action against fungal 
and parasitic infections. In the current study, low concentrations of Myrrh treatment increased 
cell survival of HSV-1 infected Vero cells. Prolonged exposure to Myrrh was found to be toxic 
to viable cells. Myrrh treatment of HSV-1 infected Vero cells was compared with ACV 
treatment of HSV-1 infected Vero cell. Myrrh treatment increased cell survival of infected Vero 
cells, similar to the effect of ACV treatment. These results provide evidence that Myrrh exerts 
antiviral effects against herpes virus infection. 
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Hypothesis 
Myrrh (Extract) will protect Vero cells from the lytic effect of HSV-1 as determined by 
increased cell survival of Myrrh-treated HSV-1 infected Vero cells compared to untreated Vero 
infected cells. 
Specific Aims:  
In the present study,  
•! The effect of Myrrh extract on cell survival of Herpes Simplex Virus Type-1 infected Vero 
cell was evaluated and compared with cell survival with Acyclovir treatment. 
•! The most effective concentration for Myrrh extract as inhibitor of HSV-1 replication was 
determined using plaque assay. 
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Introduction 
 
Ninety percent of the human population has been infected by different types of herpes 
viruses (Kukhanova et al., 2014). HSV-1 is the most common type of herpes virus and mainly 
affects the epidermal cells and epithelia of the oral mucosa (Fatahzadeh and Schwartz, 2007). 
HSV-1 causes lesions and cold sores on the lips, skin, mouth cavity, and eyes (Whitley and 
Roizman, 2001; Grünewald et al., 2003). About 300,000 HSV ocular infections are recorded in 
the USA every year (Whitley and Roizman, 2001). HSV-1 is a large, double-stranded DNA 
(Manservigi et al., 2010). The HSV-1 virion’s structure includes a capsid surrounding the viral 
DNA core and an envelope with abundant glycoprotein spikes which are critical for the 
attachment of the virus to the host cell. (Whitley and Roizman, 2001). Tegument proteins occupy 
the space between the capsid and the envelope (Fatahzadeh and Schwartz, 2007). Tegument 
proteins play essential roles in the virus replication cycle (Kim et al., 2012; Thompson et al., 
2009).  
In humans, HSV-1 has two distinct phases (Akhtar and Shukla, 2009). The first phase of 
infection is the lytic phase and second is the latent phase (Kim et al., 2012; Akhtar and Shukla, 
2009). The virus replicates during the lytic phase, when the symptoms of infection appear 
(Gilden et al., 2009; Thompson et al., 2009). The latent phase of the virus follows the lytic phase, 
during which the virus stays inactive inside the host cell (Feldman et al., 2002). During the latent 
phase, the virus infiltrates the sensory neurons and stays as a dormant virus in the sensory 
ganglia (Maillet et al., 2006; Yao, 2014; Kukhanova et al., 2014). Reactivation of the infection 
can occur later in life, causing damage and inflammation to the host (Feldman et al., 2002).  
!
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  Acyclovir (ACV) is an anti-viral drug which is prescribed as a treatment for HSV-1 
infection (Tyring et al., 2002). ACV has a suppressive effect on HSV-1 due to its ability to 
inhibit virus replication (Viggosson, 2011). ACV has two mechanisms of action. ACV is 
activated by thymidine kinase (TK) of the virus, inhibits the DE novo synthesis of viral DNA, 
and terminates the growing viral DNA chain (Viggosson, 2011; Bacon et al., 2003). Failure to 
produce viral TK or any mutation in DNA polymerase lessens the activity of ACV (Bacon et al., 
2003). Poor solubility, low oral bioavailability, and lack of absorption limit ACV usage (De 
Clercq and Field, 2006; Al-Subaie et al., 2015). Natural medicines have garnered increased 
attention recently (Shuaib et al., 2013). The low cost and higher safety of usage of natural 
medicines makes them a viable choice to replace many synthetic medicines that have the same 
effects (Shalaby and Hammoud, 2014; Shuaib et al., 2013). Myrrh is a natural product that 
consists of water-soluble gum, alcohol soluble resin, and about 3–8% essential oil (Ashry et al., 
2010; Abdul-Ghani et al., 2009; Boffa et al., 2015; Su et al., 2011). Myrrh is one of the earliest 
medicines in recorded history. It is an essential element used in perfume and incense in addition 
to its uses for medicinal purposes (Shen et al., 2012; Guyatt, 2002).!Due to its anti-inflammatory 
and cytotoxic effects, it has become a powerful treatment for various types of infections (Tipton 
et al., 2003; Shuaib et al., 2013; Langhorst, et al., 2013). Mixing Myrrh with toothpaste and 
mouthwash is a useful inhibitor for inflammation of oral fissures (Boffa et al., 2015; Guyatt, 
2002; Tipton et al., 2003). Different species of myrrh have anti-tumor and anti-proliferative 
effects that have been observed by scientists investigating myrrh’s effects on breast and colon 
cancers (Boffa et al., 2015; Abdul-Ghani et al., 2009; Shen et al., 2012; Tipton et al., 2003). 
Myrrh oil (MO) has been applied to cure paw swelling in mice (Shalaby and Hammoud, 2014). 
Reduction of skin infection, obesity, wounds, and pain are among the most promising 
!
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consequences of myrrh product application (Shuaib et al., 2013; Shalaby and Hammoud, 2014; 
El-Sherbiny and El Sherbiny, 2011; Nomicos, 2007).  
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Literature Review 
 
 
 Herpes Simplex Virus -1 (HSV-1) 
 
!
Figure 1: Structure of Herpes Simplex Virus. Double stranded DNA surrounded by 
nucleocapsid. Teguments fill the space between the capsid and the envelope Adapted from 
Manservigi et al., 2010.
 
Herpes simplex virus-1 (HSV-1) is an alpha herpes virus (Woo and Challacombe, 2007). 
It contains a large double-stranded DNA core. The virion consists of a DNA core, a capsid, and 
an envelope covered by spiky glycoprotein (Manservigi et al., 2010). The glycoproteins play an 
essential role for attachment between the virus and host cell receptor (Whitley and Roizman, 
2001). Teguments fill the space between the capsid and the envelope of the virus (Fatahzadeh 
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and Schwartz, 2007). The virion has a unique structure that protects its genetic material from the 
extracellular environment. This structure allows for easier cell penetration so the genome can be 
efficiently released into the host cell nucleus (Figure 1) (Spear, 2004). 
HSV-1 infections appear on the lips, skin, mouth, eye, and mucosal membranes (Whitley 
and Roizman, 2001). There are a number of different ways the virus can be distributed to an 
unaffected person. Direct exposures to an open sore, respiratory droplet, or body fluids are all 
associated with viral transmission (Fatahzadeh and Schwartz, 2007). 
  HSV-1 manifests itself on the gums, cheeks, or tongue, causing oral lesions and cold 
sores (Woo and Challacombe, 2007; Grünewald et al., 2003). The lesions are characterized by 
burning, itching, and painful sensations (Whitley and Roizman, 2001). Mucosal discharge is 
another way to disseminate repetitive HSV-1 infection (Woo and Challacombe, 2007). An HSV-
1 infected mother can transmit the virus to her infant during birth, causing neonatal herpes. The 
virus can also be transmitted to the fetus through cross contamination (Fatahzadeh and Schwartz, 
2007). 
Herpetic whitlow is another type of HSV-1 lesion that occurs on the fingers or nails of 
medicinal specialists who handle medical equipment while caring for infected patients (Whitley 
and Roizman, 2001). Three hundred thousand HSV ocular infections are discovered annually in 
the USA (Whitley and Roizman, 2001). Scratching an open sore and then touching the eyes can 
disseminate the herpes to the eyes and, over time, can cause a lesion over the cornea (Woo and 
Challacombe, 2007).  
  HSV-1 can also target the trigeminal nerve. The virus migrates along the nerve to the 
brain and causes encephalitis. If left untreated, encephalitis causes death in more than 70% of 
!
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cases, while only 2.5% of survivors regain normal neurological activity (Whitley and Roizman, 
2001) 
Life Cycle of the Virus:  
Entry to the host cell:  
 
 
!
Figure 2: Entry to the host cell. Essential host cell receptors and viral glycoproteins that are 
required for HSV entry. The viral envelope has been embedded with several types of 
glycoproteins (gB, gC, gD, gH and gL) essential for the penetration. Binding of gB or gC to 
heparan sulphate (HS) facilitates the attachment of HSV-1 to cells, allowing for gD to interact 
with its receptors:  HVEM, nectin-1 and nectin-2, and 3-O-sulfotransferases. Binding of gD to 
these receptors promotes fusion of the virus with a cell membrane. gB and gH-gL heterodimers 
along with gD and a gD receptor are mandatory for the fusion process. Adapted from Spear, 
2004. 
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 As previously mentioned, HSV-1 primarily enters external surface of skin or mucosa via 
glycoproteins on the virion’s envelope interacting with the receptors found on the cell surface 
(Akhtar and Shukla, 2009). Glycoproteins gB, gC, gD, gH, and gL are required for HSV1 entry 
(Shelly et al., 2012; Akhtar and Shukla, 2009). Nectin-1 and -2, herpes virus entry mediator 
(HVEM), and 3-O heparan sulfate are also important receptors involved with viral entry (Akhtar 
and Shukla, 2009; Krummenacher et al., 2002). Heparan sulfate (HS) chains have a significant 
role in facilitating HSV attachment. Binding of the virus occurs when HS interacts with gC and 
gB (Bender et al., 2005). Nectin-1 and -2 and HVEM use gD to mediate entry of the virus 
(Krummenacher et al., 2003). T lymphocytes and dendritic cells tend to use HVEM receptors, 
while nectin-1 is used by neuronal and epithelial cells (Spear, 2004; Campadelli-Fiume et al., 
2002). Interaction between gD and its receptor is a mandatory step for the fusion of the envelope 
with the cell membrane (Akhtar and Shukla, 2009). Furthermore, multi-glycoprotein 
combinations of gB, gH and gL heterodimers can carry out the fusion process (Akhtar and 
Shukla, 2009; Shelly et al., 2012; Spear, 2004; Bender et al., 2005).  
 
Replication of HSV-1:  
Replication of herpes simplex virus has multiple phases (Akhtar and Shukla, 2009). The 
first phase is called the lytic phase, while the second phase is called the latent phase. One 
prominent aspect of HSV1 is the ability to switch between production, replication, and latency 
(Kim et al., 2012). Following entry into the host cell, the virus uncoats its nucleocapsid and 
teguments are released into the host cell’s cytoplasm (Xing et al., 2013; Akhtar and Shukla, 
2009). The herpes virus capsid migrates towards the nucleus with the aid of microtubules to 
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deliver the viral genome to the nucleus of the host cell (Akhtar and Shukla, 2009; Pasdeloup et 
al., 2009; Nicoll et al., 2012). Within the host cell cytoplasm, a variety of tegument proteins are 
released (Nicoll et al., 2012; Kim et al., 2012; Thompson et al., 2009). Two of these proteins 
play roles in the replication cycle of a virus. One is virion host shut off (VHS) and the other is 
VP16 (virion protein 16) (Nicoll et al., 2012; Mossman et al., 2000). Release of these tegument 
proteins into the cytoplasm is a very important step in the viral replication cycle (Kim et al., 
2012; Thompson et al., 2009). VHS shuts off the transcription machinery of the host cell and 
also blocks the translation of the host cell messages by degrading the host mRNA in the 
cytoplasm (Mossman et al., 2000; Weir, 2001; Dauber et al., 2014; Matis and Kudelova, 2001). 
Mutations in viral VHS decrease their ability to terminate host cell protein synthesis (Weir, 
2001). On the other hand, VP16 passes through nuclear pores to the nucleus and helps in viral 
transcription by activating transcription of some early immediate genes (EI) that are required for 
the replication of the viral genome (Ghosh et al., 1996; Xing et al., 2013). When VP16 promotes 
transcription of EI genes that are used for replication, the mRNA of early genes travels out to the 
cytoplasm and is translated into early proteins (Xing et al., 2013; Mossman et al., 2000; 
Pasdeloup et al., 2009). The early proteins that are produced return to the nucleus to replicate 
viral DNA (Kim et al., 2012; Thompson et al., 2009; Mossman et al., 2000). After replication is 
complete, there are several varieties of transcriptions as early genes start to produce early and 
late genes (Mossman et al., 2000). This is the period in which lytic infection or lysogenic 
infection occurs (Nicoll et al., 2012).  In this period, late genes start to express mRNA which is 
translated to generate the late structural protein. Once the structural protein and DNA (genetic 
material) are produced, they will form a virion (Turner and Jenkins, 1997). HSV1 makes its 
capsid inside the host cell’s nucleus; after the capsid is complete, it bulges out from the nucleus 
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with the nuclear membrane surrounding it (primary envelopment) (Johnson and Baines, 2011; 
Mettenleiter et al., 2006). It then moves into the Endoplasm Reticulum, where viral proteins are 
produced (Leuzinger et al., 2005). The capsid leaves with some of these protein components 
which are involved in the formation of spikes (Leuzinger et al., 2005). The virion is transported 
to the Golgi apparatus. Inside the Golgi apparatus, the protein undergoes secondary envelopment 
and the glycoproteins of the virus are modified (Granzow et al., 2001; Mettenleiter, 2004). After 
modification, the virus is ready to leave the cell taking a part of the cell membrane as the virus is 
budding out (Owen et al., 2015). Once the HSV1 has its virion DNA, capsid and spiked 
envelope, the virus is fully mature (Johnson and Baines, 2011; Zeev-Ben-Mordehai, 2014). 
Latency Phase: 
 The absence of viral replication and failure of lytic gene expression lead to a potential 
virus phase where the host cells harbor lifelong infection (Feldman et al., 2002; Ma et al., 2014; 
Bertke et al., 2011; Thompson et al., 2009). One of the most fundamental features of HSV-1 
infection is that it can reactivate causing recurrent infections (Yao, 2014; Kukhanova et al., 
2014).  
  After maturation, the virion progressively spreads to the neighboring cells (Nicoll et al., 
2012). The virus travels through the sensory nerve until it reaches the trigeminal ganglion of the 
central nervous system (CNS) (Webre et al., 2012; Nicoll et al., 2012; Lee et al., 2015). The 
virus establishes a dormant infection in the root dorsal ganglion where the genome persists in the 
cell’s nucleus (Maillet et al., 2006; Yao, 2014; Kukhanova et al., 2014). During the latency 
phase, there is no active virus generation and symptoms do not appear in the infected patient 
(Feldman et al., 2002; Lee et al., 2015; Al-Dujaili et al., 2011). HSV-1 can reactivate 
spontaneously or due to stress, UV light, or immunosuppression (Lee et al., 2015; Feldman et al., 
!
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2002; Webre et al., 2012). As explained before, VP16 has an important role in IE genes during 
the lytic phase (Xing et al., 2013; Mossman et al., 2000; Pasdeloup et al., 2009). Therefore, 
VP16 is important in order to reactivate HSV-1 (Thompson et al., 2009). Thompson et al., 2009 
found that VP16 is required to regulate the termination of the latent cycle, re-entering the lytic 
cycle. HSV-1 migrates through the neural process back to the epithelial cell where the virus 
starts its productive cycle again (Thompson et al., 2009; Nicoll et al., 2012). The start of the viral 
replication cycle in epithelial cells causes lesions in the mouth, skin, and nasal canal which 
illustrates the reason behind patients recurrently getting cold sores in the same location (Lee et 
al., 2015; Ma et al., 2014).  
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Acyclovir: 
!! Acyclovir (ACV) is an anti-viral drug used to treat infection with herpes simplex virus 
(HSV1), varicella zoster (chickenpox), and herpes zoster (shingles) (Gopal et al., 2013; Al-
Subaie et al., 2015; Viggosson, 2011). ACV has been used as a potent and reliable suppressor of 
herpes simplex virus (HSV1) for more than 25 years (Piret and Boivin, 2011; Tyring et al., 2002; 
Viggosson, 2011). ZoviraxTM is its commercial name (Viggosson, 2011). ACV should be used 
five times a day in order to be effective (Tyring et al., 2002). The most beneficial characteristic 
of ACV is that it is a safe treatment for HSV1 (De Clercq and Field, 2006; Al-Subaie et al., 
2015; Tyring et al., 2002). ACV has the ability to attack virally infected cells while leaving the 
uninfected cells untouched (Krishnan et al., 2010; De Clercq and Field, 2006; Viggosson, 2011; 
Tyring et al., 2002). Thymidine kinase (TK) is a specific enzyme that exists only in the infected 
cell, which makes it possible to activate ACV and make it functional (Bacon et al., 2003; 
Viggosson, 2011; Tyring et al., 2002). Due to the similarity of the chemical structure of 
Acyclovir and the nucleoside guanosine (Viggosson, 2011), ACV competes with the guanosine 
nucleosides to inhibit viral replication (De Clercq and Field, 2006).  In HSV-1 infected cells, 
ACV is converted to acyclovir monophosphate by viral thymidine kinase (TK) (Piret and Boivin, 
2011; Viggosson, 2011; Tyring et al., 2002; De Clercq and Field, 2006). The second 
phosphorylation, which is mediated by guanosine monophosphate kinase, adds two more 
phosphates to the last acyclovir monophosphate to form acyclovir triphosphate (the active form) 
(Piret and Boivin, 2011; Tyring et al., 2002; Viggosson, 2011; De Clercq and Field, 2006). The 
active form of the drug works as an inhibitor of DNA polymerase (Piret and Boivin, 2011; 
Viggosson, 2011; De Clercq and Field, 2006; Krishnan et al., 2010; Bacon et al., 2003). 
Triphosphate ACV suppressed DNA polymerase about ten to thirty fold (Viggosson, 2011).!
!
!12!
Furthermore, ACV is considered an obligate DNA terminator when it is incorporated into the 
herpes virus DNA chain (De Clercq and Field, 2006; Viggosson, 2011). ACV’s active form does 
not have a hydroxyl group, which is normally located in position 3, thus blocking chain 
elongation (Piret and Boivin, 2011).  
ACV limitation and resistance: 
There are two common reasons for ACV resistance by HSV1. Mutation of the viral TK 
causes insufficiency of the ACV phosphorylation process, which prevents its therapeutic value 
(Tyring et al., 2002; Bacon et al., 2003). Mutation of the DNA polymerase of the virus can be 
another reason for a lack of ACV activity (Bacon et al., 2003). This leads to the inability to 
integrate acyclovir triphosphate in the DNA molecules (Tyring et al., 2002). Moreover, ACV has 
limitations due to its low solubility in water so it can not be used as a muscular injection or in 
eye drops. Lack of absorption by transdermal application is another factor restricting ACV usage 
(De Clercq and Field, 2006; Al-Subaie et al., 2015).        
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Figure 3: Resemblance between Acyclovir and Guanosine 
chemical structure. Adapted from Viggosson, 2011. 
Figure 4: Mechanism of ACV. Inactive ACV is phosphorylated 
by HSV-1 Thymidine Kinase. Two more phosphorylations 
activate ACV. Acyclovir triphosphate inhibits HSV-1 replication. 
Adapted from Piret and Boivin, 2011. 
!
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   Myrrh 
!
  Figure 5: Pictures for Myrrh Tree from South Region of Saudi Arabia. 
 
The repetitive use of antibiotics to treat bacterial disease can cause antibiotic resistance. 
This has led to a search for medical herbs as an alternative medicine to avoid many different side 
effects. Medicinal herbs have been used around the world since ancient times (Shuaib et al., 
2013). Natural medical extracts can be more viable, cheaper, and safer compared to synthetic 
drugs. The World Health Organization reports that 90% of the world’s population relies on 
traditional medicine (Shalaby and Hammoud, 2014; Shuaib et al., 2013).  
Myrrh has been confirmed in the USA by the Food and Drug Administration as a safe 
substance for use in foods and drinks and as a fragrance in beauty agents (Shalaby and 
Hammoud, 2014; Abdul-Ghani et al., 2009). Myrrh is a yellow resinous exudate which is 
harvested from the trunk of the small Myrrh tree (Su et al., 2011; Shalaby and Hammoud, 2014; 
!
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Guyatt, 2002). Many previous studies identify Myrrh as one of the oldest herbs utilized in 
perfumes and medicines (Abdul-Ghani et al., 2009; Boffa et al., 2015). Water-soluble gum (30–
60%), alcohol soluble resin (20–40%), and essential oils (3–8%) are the main substances that 
come form Myrrh (Ashry et al., 2010; Abdul-Ghani et al., 2009; Boffa et al., 2015; Su et al., 
2011). Myrrh has been used in perfume and incense commercially as well as medically (Shen et 
al., 2012; Guyatt, 2002). Due to its anti inflammatory, cytotoxic, and bacterial activities, myrrh 
has been used to cure many infections (Tipton et al., 2003; Shuaib et al., 2013; Langhorst, et al., 
2013). Myrrh reduces inflammation of the oral cavity (Tipton et al., 2003) and has been added to 
toothpaste and mouthwash for this purpose (Boffa et al., 2015; Guyatt, 2002). For more than 50 
years, mixing myrrh with chamomile flowers and coffee charcoal has been a useful treatment for 
diarrhea (Langhorst, et al., 2013; Nomicos, 2007). According to Shalaby and Hammoud, (2014) 
Myrrh extract has analgesic and anti-inflammatory activity, controls weight gains and adjusts 
blood lipid levels in rats. In additional experiments, myrrh oil inhibited paw swelling in rats with 
a 100 mg/kg dose after 4 hours (Su et al., 2011). Different species of myrrh have anti-tumor and 
anti-cell proliferation effects. Myrrh has been used to treat breast and colon cancer (Boffa et al., 
2015; Abdul-Ghani et al., 2009; Shen et al., 2012; Tipton et al., 2003). The average number of 
intestinal schistosomiasis eggs decreased from 181 eggs per gram to only 4.0 eggs per gram in 
patients treated with Myrrh (Tipton et al., 2003; Abdul-Ghani et al., 2009). Myrrh has also been 
used to treat trauma, skin infections, and fevers (Shuaib et al., 2013; Shalaby and Hammoud, 
2014; El-Sherbiny and El Sherbiny, 2011; Nomicos, 2007). Both gram-negative and gram-
positive bacterial strains are inhibited by Myrrh (Boffa et al., 2015; Abosalif et al., 2015; Shuaib 
et al., 2013). Recently, scientists examined the bioactivity of Myrrh on fresh salad as a natural 
preservative. Myrrh extended the shelf life of the product by lowering bacteria growth (Boffa et 
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al., 2015). A commercial drug called Mirazid containing 300 mg of purified myrrh is confirmed 
as an effective drug against many parasites (Shalaby and Hammoud, 2014; Boffa et al., 2015; 
Shen et al., 2012). Mirazid is an anti-parasitic which kills all worms of S.mansoni in four weeks 
and eliminate most of the symptoms associated with the parasite within one week (Abdul-Ghani 
et al., 2009; Yakoot, 2010; Shen et al., 2012). Yakoot (2010) reported a cure rate of more than 
90% for most experiments using Mirazid.   
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Materials and Methods 
Herpes simplex virus-1  
Herpes simplex virus-1 was initially obtained from Dr. Nancy Sawtell, Children's 
Hospital Medical Center, Cincinnati, OH. Vero cells were infected at 90-100% confluency with 
1 ml HSV-1 at 0.1 MOI and once the cells were rounded, the supernatant was harvested, 
aliquoted and stored at -80°C. Virus was tittered before being used for further experimentation. 
Plaque Assay 
The plaque method has been used to quantify infectious virus through counting of 
plaques (zones of killed cells) on virus-infected Vero cells. Vero cells were grown in 12 well 
plates until they reached 90-100% confluence. HSV-1 was added and the plate was incubated for 
two hours to ensure that the Vero host cell absorbed the virus. Following virus infection, 1 ml of 
methyl cellulose (MC) was added to each well. MC is used to prevent the!diffusion and spread of 
virus. Following the overlaying of MC, plates were incubated for 3-5 days. Monolayers were 
fixed using 4% formaldehyde and kept at room temperature overnight. The fixative was then 
removed and the monolayers were stained using 5% Crystal Violet for about 10- 15 minutes. All 
wells were gently washed with distilled water (dH2O) and the plate was allowed to dry at room 
temperature and plaques counted. The following equation was used to calculate the viral titer.  
 Average # Plaques = PFU/ml  
    D x V     
D=dilution V=Volume of diluted virus added to the plate 
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Vero cell  
The Vero cell line is used as a host cell for the virus growth. The cell line was derived 
from the kidney of an African green monkey (CCL-81, ATCC). The culture medium was 
prepared using 90% of Dulbecco’s Modified Eagle’s Medium (DMEM), 10% fetal bovine serum 
(FBS), and 1% penicillin/streptomycin. The cell growth was monitored every day and cells were 
split every 2-3 days. DMEM, FBS and antibiotics were purchased from Fisher Scientific.  
Acyclovir (ACV) treatment before infection 
Vero cells were cultured using 12 well tissue culture plates (Fisher Scientific) for 24 
hours. The cells were treated with ACV using different doses (2, 1, and, 0.05 µg /ml of medium) 
and incubated for 2 and 4 hours. Then cells were infected with HSV-1 at 0.1 MOI and incubated 
for 2 hours at 37°C in 5% CO2. Following virus infection, 1 ml of methyl cellulose (MC) were 
added. Monolayers were fixed with 4% formaldehyde overnight. The fixative was removed and 
monolayers were stained using 5% Crystal Violet for about 10-15 minutes. Plates were washed 
with distilled water (dH2O) and the plaques were counted.  
ACV treatment after infection  
Vero cells were grown in 12 well plates with 10% DMEM overnight. The next day, cells 
were infected with HSV-1 at 0.1 MOI for 2 hours. After the virus in medium was aspirated, 
plates were incubated in culture medium containing ACV for 2 and 4 hours. The effect of virus 
was examined using plaque assay.   
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Myrrh treatment before infection 
Vero cells were cultured in 12 well tissue culture plates. After 24 hours, Myrrh extracts 
were added at different concentrations (1%, 2%, 0.5%) for 2 and 4 hours. After that, cells were 
infected with HSV-1 at 0.1 MOI and incubated for 2 hours at 37°C. One ml Methylcellulose was 
added to each well and the dishes were incubated for 3-5 days. Monolayers were fixed with 4% 
formaldehyde overnight then stained with 5% Crystal Violent for 10-15 min. Plates were washed 
with distilled water (dH2O) and the plaques were counted.  
Myrrh treatment after infection  
Vero cells were plated in 12 well tissue culture plates with 10% DMEM and incubated 
overnight. Then, cells were infected with HSV-1 at 0.1 MOI for 2 hours. After the virus was 
aspirated, plates were incubated in culture medium containing different doses of myrrh extract 
for 2 and 4 hours. The effect on virus infectivity was examined using plaque assay.  
 
Cell viability  
Vero cells were grown until 90- 100% confluence. They were treated with Myrrh for 2 or 
4 hours either before or after virus infection. Infected, untreated cells were used as a control. 
Vero cells were washed using Phosphate-buffered saline (PBS). Trypsin was added to the cells. 
After cells were detached, 10% DMEM was added. Detached cells were centrifuged at 1500 rpm 
(4 ̊C) for 5 minutes. One ml of fresh medium was added to the cell suspension. 20 μl of the 
suspended cells were mixed with 20 μl Trypan blue dye (Fisher Sciences) to analyze cell 
viability. Aemocytometer was used to count viable cells. The following equation was used to 
count cell viability:  
!
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Cell Viability (%) = total viable cells (unstained) ÷ total cells (stained and unstained) ×100  
Statistical Significance: 
  All experiments were repeated three times to confirm the results. Data were analyzed by 
one-way ANOVA (Sigma Plot 12.0, YSTAT). Data are represented as mean ± SEM.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
!
!21!
RESULTS  
Toxicity of Myrrh on Vero cell 
Inhibition of the viral cytopathic effect of Myrrh on the Vero cell by Myrrh was 
examined using different concentrations of Myrrh. Infected Vero cells were treated with 20% or 
10% concentrations of Myrrh. High concentrations of Myrrh were toxic as shown in Figure 6A. 
However, infected Vero cells treated with lower concentrations of Myrrh (2%, 1%, and 0.5%) 
survived as shown in Figure 6B. Toxicity was determined visually by cell density of the infected 
treated cells compared with the controls infected, untreated Vero cells.  
Effect of Myrrh extract on HSV-1 infection (2 hours before infection): 
 Cultured Vero cells at 90% confluence were treated with 2%, 1%, and 0.5% 
concentrations of Myrrh two hours before HSV-1 infection. Cell density reached highest value at 
2% concentration (P value ≤ 0.001) while 0.5% concentration of Myrrh was the lowest!(P value 
≤ 0.01), compared with the untreated, virus-infected cells (see figure 7). 
Effect of Myrrh extract on HSV-1 infection (2 hours after infection) 
Cultured Vero cells (at 90- 100% confluence) were treated with different concentrations 
of Myrrh (2%, 1%, and 0.5%) at 2 hours post HSV-1 infection. At two hours, there was a 
significant reduction (P value ≤ 0.001) in the number of plaques formed at all Myrrh 
concentrations compared to the control (virus infected cells). Myrrh was most effective at 2% 
concentration on virus infected cells compared to other concentrations (Figure 8). Analyzing cell 
density using Image J gave the same results as shown in Figure 9. Densities of the treated cells 
decreased with the reduction of the concentrations of Myrrh compared with the control (virus 
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infected cell). 
Effect of Myrrh extract on HSV-1 infection (4 hours before infection)   
Plaque assays were used to detect the concentration of Myrrh that most effectively 
inhibited virus replication. Before HSV-1 infection, Myrrh treatment was added for 4 hours 
using different concentrations (2%, 1%, and 0.5%). A 4 hour treatment with 0.5% concentration 
of Myrrh before virus infection displayed a significant result (p value .031) compared to virus 
infected cell (control), while (1% and 2%) concentrations of Myrrh showed a slight reduction 
compared with the control Figure 10.  
 
Effect of Myrrh extract on HSV-1 infection (4 hours after infection)   
Vero cell were grown to approximately 90-100% confluence. They were treated with 
Myrrh 4 hours after virus infection and the cells were stained with crystal violet to determine the 
cells that survived the infection. Concentrations of Myrrh 2% and 1% led to insignificant 
increase in cell survival density compared to the control (infected Vero cells). As shown in 
Figures 11 there was a significant difference (p value .008) between the 0.5% concentration and 
the control (infected untreated cells). 
 
Cell Viability comparison between 2 and 4 hours treatment of Myrrh 
There was notable decrease in the cell viability percentage at 2% and 0.5% 
concentrations between 2 hrs and 4 hrs of Myrrh treatment. Cell viability percentage was 
significantly increased higher at 2 hrs treatment compared to 4 hrs treatment (P value ≤ 0.001) as 
shown in Figures 12 A and C. However, 1% concentration of Myrrh treatment led to a less 
significant difference then 2% and 0.5% (P value 0.048) Figure 12 B. 
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Comparison of ACV or Myrrh treatment at 2 hours before and after infection  
The scanned pictures were analyzed using Image J. Pixel densities for each of the three 
random wells were analyzed using Sigma Plot statistic. No significant differences in cell survival 
were found using a one-way analysis of variance between the ACV and Myrrh treatments at 2%, 
1% and 0.5% concentrations at 2 hours before infection (Figure 13). 
After 2 hours of the ACV or Myrrh treatments followed by HSV-1 infection, infected 
Vero cells treated with ACV showed greater survival rates (P value ≤ 0.001) relative to infected 
Vero cells treated with Myrrh in all concentrations (Figure 14).  
 
Comparison of ACV or Myrrh treatment at 4 hours before and after infection:  
   At 4-hours the Myrrh treatment displayed significant results only for the 0.5% 
concentration. As shown in Figure 15, cell survival with ACV at a 0.5% treatment significantly 
increased survival compared to the Myrrh treatment before infection (P value ≤ 0.001) and after 
infection (P 0.01). 
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(A) 
 
 
 
 
                                                                                                            (B) 
 
             Figure 6. Toxicity of Myrrh on Vero cells after infection with 0.1 MOI of virus.  
(A) 10% and 5% concentrations of myrrh caused cell death while lower concentrations of 
2%, 1% and 0.5% protect against cytopathic effect (B). 
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Figure 7. Effects of different concentrations of Myrrh treatment 2 hours before HSV-1 
infection. Pixel Density of cell survival of infected treated cells using different concentrations 
(2%, 1%, and 0.5%) significantly increases compared with control untreated infected cells. Vero 
cells infected with HSV-1 that were treated with 2% Myrrh concentration 2 hours before 
infection, have a greater survival rate compared cells treated with other Myrrh concentrations. 
(ME: Myrrh Extract; *** =P value ≤ 0.001; **=P value ≤ 0.01)  
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Figure 8. (A) The number of plaques formatted after two-hours Myrrh treatment prior to HSV-1 
infection. The number of plaques for the treated cells decreased significatly at all concentrations 
compared with the control (untreated HSV-1 infected Vero cells). (ME: Myrrh Extract; *** =P 
value ≤ 0.001). (B) Plaque Assay plates at two-hours treatment with different concentrations of 
Myrrh following infection. There was a substantial reduction on the formation of plaques at all 
Myrrh treatment concentrations compared with the control (Vero infected cells).  
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Figure 9. Comparison of Myrrh added 2 hours after HSV-1 infection 2 hours to infected 
untreated cells (control). Myrrh treatment for 2 hours after virus infection, resulted in a 
significant increase in cell survival at all concentrations compared with the control untreated 
infected cells. (ME: Myrrh Extract; *** =P value ≤ 0.001; **=P value ≤ 0.01)  
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Figure 10. Comparison of HSV-1 cytopathic effects of Vero cells treated with Myrrh 4 hours 
before infection. Pixel Density (cell survival) of scanned images of cells treated with different 
concentrations of Myrrh. There was a significant increase in cell survival at 0.5% of Myrrh 
compared to the control (infected, untreated cells) (* P=value .031; ME: Myrrh Extract).  
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Figure 11. Myrrh effect on infected Vero cells added 4 hours following infection. Cell survival 
significantly increased only at 0.5% concentration (** P value 0.008) compared to the control 
(infected, untreated cells) (ME: Myrrh Extract).  
  
Pi
xe
l D
en
si
ty
 (c
el
l s
ur
vi
va
l) 
 
!
!30!
!
! !
                                  (A) (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) 
                                                      
 
 
Figure 12: Comparison of present cell viability between 2 and 4 hours of Myrrh pretreatment. 
(A) Cell viability percentage increased significantly at 2hrs (P value < 0.001) and at 4 hrs (P 
value < 0.001) of 2% myrrh treatments compared with the control (infected, untreated cells). 
Pretreatment with 2 hours led to a significantly higher survival than the 4 hours treatment (P 
value < 0.001). Figure (B) Cell viability percentage increased significantly at 2hrs (P value < 
0.001) and 4 hrs (P value < 0.001) compared with the control. However, the differences between 
2 hrs and 4 hrs of 1% of Myrrh were nearly insignificant (P value = 0.048). (C) At 0.5% 
concentration of Myrrh cell survival was greater at 2hrs compared to 4 hrs of treatment (P value 
< 0.001) (ME: Myrrh Extract). 
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           2% concentration of ACV or Myrrh                                             1% concentration of ACV or Myrrh                         
  
 
 
 
  
                                                         0.5% concentration of ACV or Myrrh                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Comparison of cell survival between Myrrh or ACV treatments 2 hours before 
infection with HSV-1. There was a significant difference in cell survival in ACV and Myrrh 
compared to the control (infected untreated cell) (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001). 
There was no significant difference between ACV and Myrrh at any concentration (ns= not 
significant) (ME: Myrrh Extract). 
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             2% concentration of ACV or Myrrh                             1% concentration of ACV or Myrrh                                               
 
 
 
 
 
 
 
 
 
                                            0.5% concentration of ACV or Myrrh ACV  
 
 
 
 
 
 
 
 
Figure 14. Comparison of cell survival between treatment with Myrrh or ACV of HSV-1 
infected cells (2 Hours treatment after infection). There was a notable increase in cell survival 
between the ACV and Myrrh treatment compared to the control (infected untreated cell). Also 
infected Vero cells treated with ACV showed greater survival rate relative to infected Vero cells 
treated with Myrrh in all concentrations. (** P ≤ 0.01; *** P ≤ 0.001) (ME: Myrrh Extract). 
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Figure 15. Comparison of cell survival between Myrrh or ACV treatments of HSV-1 infected 
cells (4 Hours treatment). (A) At 4 hours treatment with ACV before infection led to a 
significant increase in cell survival compared to Myrrh (P value< 0.001). (B) Treatment with 
ACV at 4 hours after infection significantly increased cell survival compared to Myrrh (P ≤ 0.01) 
(ME: Myrrh Extract). 
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Discussion 
Myrrh has been used in Middle Eastern countries for centuries, not only as a foaming 
material but also as a medication. Recently, researchers have demonstrated that myrrh has 
antibacterial effects against gram positive bacteria such as Bacillus subtilis and Staphylococcus 
aureus. Myrrh application has shown promising action against pathogenic Gram- negative 
bacteria such as Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Pseudomonas 
aeruginosa. Myrrh also effectively inhibits fungal pathogenic growth of Candida albicans and 
Apergillus niger (Abosalif et al., 2015). Myrrh is used as an anti-parasitic agent to treat human 
trematode infections. Researchers have examined the anti-parasitic effect of myrrh with 
exploring its mode of action, safety, and efficacy on parasite infections (Abdul-Ghani et al., 
2009).  
In the current study, Myrrh extract’s effect was examined on Vero cells infected with 
Herpes Virus Type-1. High concentration (10% and 5%) of Myrrh extracts were toxic to the 
Vero cells, while lower concentrations (2%, 1%, and 0.5%) were protective for Vero cells 
against the cytopathic effect of HSV-1. 
Application of Myrrh Extract for 2 hours at lower concentrations of 2%, 1% and 0.5% 
showed significant reduction in the HSV-1 viral replication. The results were compared with 
infected untreated cells using plaque assay and confirmed by testing cell viability.  
NF-kB is activated in HSV-1 infected Vero cells leading to increase secretion of pro-
inflammatory cytokines secretion including IL6, IL8, TNF-α, and interferons (Li et al., 2006). 
Epithelial cells’ ability to act as accessory immune cells is a possible explanation for the 
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significant reduction in the virus’ cytopathogenic effect on Myrrh treated Vero cells (Tipton et 
al., 2003). The treated Vero cells may lead to a decrease in the production of IL-1B, which in 
turn can reduce the production of cytokines caused by HSV-1, such as IL6 and IL8 (Tipton et al., 
2003). This hypothesis is worthy of further investigation in future studies.     
AT 4 hours of Myrrh treatment, the 0.5% is the only concentration that showed 
significant reduction in cytopathogenicity before and after virus infection. 2% and 1% 
concentrations of Myrrh resulted in insignificant reductions. This phenomenon could be due to 
prolonged exposure to high toxic concentrations of Myrrh Extract that led to normal cell death.  
This explains why in middle eastern countries, Myrrh extract is applied to the area surrounding 
the wound and prohibited over the legion.  
One possible mechanism of Myrrh treatment on HSV-1 infected cells could be that myrrh 
blocked the virus entry to the Vero cell and this could explain the effect that myrrh treatment 
before infection shows a significant increase in cell survival in all tested concentrations.  This 
effect could inhibit new progeny of virus to enter new Vero cells when myrrh treatment is used 
after infection. The other possibility could be Myrrh treatment has effects on metabolic activity, 
cell membrane integrity, and IL-1B stimulated production of IL-6 and IL-8 by that lead to 
cytotoxic effects on infected Vero cells. 
Future Study  
Myrrh application is a very promising natural medicine that has been applied in ancient 
countries as an anti-inflammatory treatment for many infection diseases. Myrrh products have 
been used as mouthwashes and for wound cleaning in many countries. It will be beneficial to 
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investigate myrrh’s therapeutic effects on many other pathogenic micro-organisms such as 
Lactobacillus microbiota (a causative agent of bacterial vaginosis), candida (the causative agent 
of candidiasis), chlamydia trachomatis (the causative agent of epididymal infertility and eye 
infection) among others. 
Peppermint Oil is an approved inhibitor of HSV-1!(Schuhmacher et al., 2003). 
Examination of Myrrh Oil and comparison of its effects with those of the Myrrh Extract used in 
our study will broaden the spectrum of applications of Myrrh on many pathogenic organisms.  
 Myrrh treatment inhibits the secretion of pro-inflammatory cytokines of microphages 
(Kim et al., 2012). It would be beneficial to examine Myrrh effects on HSV-1 infected 
microphages M1 and M2 by studying the differences in cytokine and interferon levels before and 
after Myrrh treatment. Myrrh treatment elevated leukocyte levels even in the absence of injury; 
this suggest that Myrrh acts as a foreign body and initiates an immune response (Haffor et al., 
2010). Future studies can investigate Myrrh effects on both T and B lymphocytes in the HSV-1 
infected model animal.  
Application of Myrrh with ACV treatment in many patients may lead to a decrease in the 
therapeutic dose and side effects associated with ACV such as nausea, diarrhea, dizziness or 
headache. It could also minimize the unusual bruising or bleeding that occurs in some 
individuals. Myrrh also could be beneficial in patients who develop a resistance to ACV or those 
with decreased absorption or abnormal TK activity.  
Application of Myrrh extract to HSV-1 infected Vero cells showed promising results in 
our experiment. Future studies should investigate the possibility of similar effects on human 
epithelial cell lines because of the close similarities between both tissues.     
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The affect of Myrrh on viruses using different entries mechanisms should be examined. 
Labeling some virus components such as glycoproteins (gB, gC, gD,gH, or gL ) may help clarify 
the effect of Myrrh treatment in inhibiting the virus invasion and or transit within infected host 
cells. HSV-1 uses F-actin to enter the host cell and microtubule to travel through the neuron; it 
would be interesting to label the microtubule associated proteins such as dynein and kinesin with 
a florescent dye and further examine Myrrh effects on blocking the movement of a virus.    
!
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